Novo Nordisk A/S (NVO.US) Q4 2025 Earnings Conference Call
Live time: Feb 4, 2026 12:00 UTC
Novo Nordisk A/S (NVO.US) Q4 2025 Earnings Conference Call
Live time: 02/04/2026 12:00:00 UTC
诺和诺德公司 (NVO.US) 2025 年第四季度业绩电话会
Summary
00:30
Opening Remarks by Michael Ligert
Michael Ligert, Head of Investor Relations, welcomes participants to Novo Nordisk's 2025 Q4 earnings call, explaining the structure of the meeting and introducing key executives who will present today.
02:24
CEO Mike Duisberg Strategic Overview
CEO Mike Duisberg outlines Novo Nordisk's 2025 achievements, including a 10% sales growth and a doubling of sales and operating profit since 2019. He highlights the strategic focus on obesity and diabetes and mentions exciting results from recent clinical trials.
03:47
Executive Team Changes
Novo Nordisk announces executive management changes, with Jamie Miller and Hung Chao joining the team, following departures of key members Dave and Ludovic.
08:14
Business Segment Performance
Various executives report performance in different segments, highlighting GLP-1 market growth and the expansion of Wigovy's sales in international markets.
18:39
R&D Updates by Martin Hoatzlanger
Martin Hoatzlanger provides updates on R&D, commenting on the promising results from trials involving diabetes and cardiovascular treatments, enhancing Novo Nordisk's portfolio.
28:00
Financial Overview by Carsten Mognussen
Carsten Mognussen shares Novo Nordisk's financial results, indicating impacts from acquisitions, restructuring, and outlines the dividend payout plans for shareholders.
37:22
Q&A Session — Analyst: James Bagley (Goldman Sachs)
Carsten Mognussen discusses the impact of pricing adjustments and strategic investments on sales trends and future market dynamics in response to analyst inquiries.
41:59
Q&A Session — Analyst: Satya Lain (Bank of America)
Carsten Mognussen addresses inquiries about the guidance changes and factors influencing sales forecasts.
Related Notices
Novo Nordisk AS | (6-K) Report by foreign issuer of material events
Feb 17, 2026 06:10
Novo Nordisk AS | (6-K) Report by foreign issuer of material events
Feb 11, 2026 16:09
Recent Live Streams
Risk Disclaimer: The content on this page represents the author's personal opinions for general information purposes only and should not be used as a basis for any specific investment, business or commercial decision. It does not represent the position of Longbridge, and the platform makes no guarantees or commitments regarding the authenticity, accuracy or originality of the above content.